Primary Site >> Colorectal Cancer
Gene >> NRAS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Activated N-ras in a human rectal carcinoma cell line associated with clonal homozygosity in myb locus-restriction fragment polymorphism. PMID: 3017909 |
Ref: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. PMID: 3041218 |
Ref: 12th codon mutation resulting in c-N-ras activation in acute myelogenous leukemia. PMID: 3278172 |
Ref: Sodium butyrate suppresses the transforming activity of an activated N-ras oncogene in human colon carcinoma cells. PMID: 2676572 |
Ref: Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. PMID: 1855226 |
Ref: Rare frequency of activation of the Ki-ras gene in rat colon tumors induced by heterocyclic amines: possible alternative mechanisms of human colon carcinogenesis. PMID: 8352890 Ref: Mutations in the p53 suppressor gene do not correlate with C-k-ras oncogene mutations in colorectal-cancer. PMID: 21573526 |
Ref: Ras oncogene activation in benign and malignant colorectal tumours. PMID: 7571058 |
Ref: Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. PMID: 8692875 |
Ref: N-ras protein: frequent quantitative and qualitative changes occur in human colorectal carcinomas. PMID: 9180144 Ref: [Detection of ras gene mutation in various stages of gastric cancer by PCR/RFLP SSCP and DNA sequencing]. PMID: 10436968 |
Ref: Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. PMID: 9699522 |
Ref: Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. PMID: 10652438 |
Ref: Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. PMID: 15781617 |
Ref: Recurrent KRAS codon 146 mutations in human colorectal cancer. PMID: 16969076 |
Ref: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. PMID: 17133351 Ref: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. PMID: 17314276 |
Ref: Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. PMID: 18372904 Ref: In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. PMID: 18524847 |
Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: Genetic pathways to colorectal cancer. PMID: 19576232 Ref: Oncogenic activating mutations are associated with local copy gain. PMID: 19671679 |
Ref: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PMID: 20098682 Ref: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. PMID: 20233444 Ref: Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. PMID: 20563247 Ref: NRAS mutations are rare in colorectal cancer. PMID: 20736745 |
Ref: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. PMID: 21239505 Ref: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. PMID: 21305640 Ref: Molecular predictors of response to chemotherapy in colorectal cancer. PMID: 21427555 Ref: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. PMID: 21641636 Ref: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. PMID: 21704278 Ref: Development of molecular biomarkers in individualized treatment of colorectal cancer. PMID: 21729679 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 |
Ref: Emerging role of cetuximab in the treatment of colorectal cancer. PMID: 22264223 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. PMID: 22427190 Ref: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. PMID: 22665543 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. PMID: 22869096 Ref: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. PMID: 23045248 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 |
Ref: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. PMID: 22647972 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. PMID: 23165447 Ref: Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. PMID: 23274911 Ref: Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. PMID: 23281932 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. PMID: 23400451 Ref: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? PMID: 23429431 Ref: Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. PMID: 23592171 Ref: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. PMID: 23725851 Ref: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. PMID: 23741067 Ref: Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. PMID: 23832066 Ref: Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. PMID: 23943423 Ref: Morphological change of a laterally spreading rectal tumor over a short period. PMID: 23957258 Ref: Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. PMID: 24006859 Ref: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. PMID: 24024839 Ref: Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. PMID: 24025413 Ref: Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. PMID: 24042191 Ref: PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. PMID: 24156022 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: Evaluating many treatments and biomarkers in oncology: a new design. PMID: 24248692 Ref: Personalized treatment for advanced colorectal cancer: KRAS and beyond. PMID: 24294007 Ref: Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PMID: 24339949 |
Ref: Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. PMID: 24006244 Ref: BRAF inhibitors in cancer therapy. PMID: 24325952 Ref: Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. PMID: 24379162 Ref: [Clinical application of next-generation sequencing technologies to achieve cancer precision medicine]. PMID: 24423944 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: Mutational analysis and clinical correlation of metastatic colorectal cancer. PMID: 24500602 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. PMID: 24582914 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. PMID: 24621249 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. PMID: 24703531 Ref: Genetic mechanisms in interval colon cancers. PMID: 24705641 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. PMID: 24799053 Ref: Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. PMID: 24806883 Ref: Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. PMID: 24832158 Ref: The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. PMID: 24857065 Ref: KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. PMID: 24859998 Ref: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. PMID: 24942275 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. PMID: 24996433 Ref: Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. PMID: 25009008 Ref: Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. PMID: 25032217 Ref: Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. PMID: 25110411 Ref: Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. PMID: 25164765 Ref: Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. PMID: 25246275 Ref: High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. PMID: 25262986 Ref: Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. PMID: 25277205 Ref: Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. PMID: 25293556 Ref: Colorectal cancer in Chinese patients: current and emerging treatment options. PMID: 25336973 Ref: Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. PMID: 25337237 Ref: Panitumumab in the treatment of colon cancer: A biomarker dilemma. PMID: 25374966 Ref: Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. PMID: 25427581 Ref: Management of colorectal cancer. PMID: 25580262 Ref: Molecular pathology of colorectal cancer. PMID: 25693079 Ref: Colorectal Cancer: Personalized Therapy. PMID: 26676107 Ref: Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. PMID: 26842186 |
Ref: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. PMID: 24791855 Ref: Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. PMID: 24806288 Ref: Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. PMID: 25248381 Ref: Medullary carcinoma of the colon: can the undifferentiated be differentiated? PMID: 25339302 Ref: Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. PMID: 25373533 Ref: Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. PMID: 25378536 Ref: Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? PMID: 25420993 Ref: Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PMID: 25472647 Ref: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. PMID: 25491172 Ref: Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. PMID: 25605843 Ref: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. PMID: 25623215 Ref: Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. PMID: 25623536 Ref: External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. PMID: 25657200 Ref: Molecular markers predictive of chemotherapy response in colorectal cancer. PMID: 25663616 Ref: FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. PMID: 25666295 Ref: Novel molecular insights from routine genotyping of colorectal carcinomas. PMID: 25683705 Ref: Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. PMID: 25688736 Ref: Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. PMID: 25712343 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. PMID: 25742472 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. PMID: 25800101 Ref: Personalized treatment for patients with colorectal cancer: role of biomarkers. PMID: 25808438 Ref: Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. PMID: 25851630 Ref: RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. PMID: 25859555 Ref: Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. PMID: 25920435 Ref: Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma. PMID: 25926041 Ref: FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. PMID: 25937522 Ref: RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. PMID: 25944693 Ref: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PMID: 25954997 Ref: Endoscopic ultrasound fine-needle aspiration cytology mutation profiling using targeted next-generation sequencing: personalized care for rectal cancer. PMID: 25972331 Ref: [Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma]. PMID: 25975908 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: RAS status in Korean patients with stage III and IV colorectal cancer. PMID: 25997687 Ref: Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. PMID: 26029459 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26030179 Ref: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. PMID: 26074686 Ref: Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. PMID: 26077270 Ref: Identification and characterization of RET fusions in advanced colorectal cancer. PMID: 26078337 Ref: Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. PMID: 26137573 Ref: Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples. PMID: 26163758 Ref: Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping. PMID: 26189770 Ref: Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. PMID: 26220423 Ref: Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. PMID: 26226847 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. PMID: 26231173 Ref: Coexisting KRAS and NRAS mutations in colon cancer. PMID: 26243064 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. PMID: 26322950 Ref: KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? PMID: 26325103 Ref: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. PMID: 26327923 Ref: The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. PMID: 26335936 Ref: Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. PMID: 26343581 Ref: KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. PMID: 26352110 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PMID: 26375816 Ref: Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. PMID: 26435479 Ref: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. PMID: 26439693 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. PMID: 26460303 Ref: Optimizing Anti-EGFR Therapy in Colorectal Cancer. PMID: 26463710 Ref: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. PMID: 26498038 Ref: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. PMID: 26508446 Ref: Absolute Quantification of Endogenous Ras Isoform Abundance. PMID: 26560143 Ref: Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. PMID: 26673925 Ref: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. PMID: 26691448 Ref: Impact of somatic mutations on patterns of metastasis in colorectal cancer. PMID: 26697197 |
Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. PMID: 26350752 Ref: Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. PMID: 26438111 Ref: Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis. PMID: 26471487 Ref: Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. PMID: 26536055 Ref: RAS testing in metastatic colorectal cancer: advances in Europe. PMID: 26573425 Ref: Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. PMID: 26661077 Ref: A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. PMID: 26666825 Ref: Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types. PMID: 26712868 Ref: Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? PMID: 26824184 Ref: The State of the Art in Colorectal Cancer Molecular Biomarker Testing. PMID: 26849815 Ref: Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 26869800 Ref: The Report of KRAS Mutation and NRAS Wild Type in a Patient with Thyroid Metastasis from Colon Cancer: a Rare Case Report. PMID: 26870147 Ref: Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. PMID: 26909603 Ref: Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. PMID: 26917275 Ref: Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. PMID: 26927802 Ref: Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/beta-catenin signaling pathway mutations. PMID: 26998897 Ref: Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. PMID: 27002107 Ref: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. PMID: 27004837 Ref: Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. PMID: 27017409 Ref: Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. PMID: 27026089 Ref: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. PMID: 27034809 Ref: Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics. PMID: 27037031 Ref: Prognostic impact of mutation profiling in patients with stage II and III colon cancer. PMID: 27074743 Ref: Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. PMID: 27083443 Ref: Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PMID: 27101000 Ref: NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing. PMID: 27121310 Ref: (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. PMID: 27146067 Ref: Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing. PMID: 27155048 Ref: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. PMID: 27218826 Ref: Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. PMID: 27221845 Ref: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. PMID: 27246726 Ref: Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. PMID: 27248473 Ref: Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. PMID: 27270901 Ref: Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. PMID: 27272216 Ref: Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. PMID: 27283768 Ref: Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. PMID: 27284437 Ref: Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PMID: 27300552 Ref: Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. PMID: 27302833 Ref: Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). PMID: 27335808 Ref: Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. PMID: 27341591 Ref: Mutation spectra of RAS gene family in colorectal cancer. PMID: 27394063 Ref: Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. PMID: 27401719 Ref: CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. PMID: 27435270 Ref: Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. PMID: 27499925 Ref: Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer. PMID: 27526306 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: Role of targeted therapy in metastatic colorectal cancer. PMID: 27672422 Ref: Multi-Center Evaluation of the Fully Automated PCR-Based Idylla KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PMID: 27685259 Ref: Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. PMID: 27712015 Ref: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. PMID: 27729614 Ref: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. PMID: 27737711 Ref: Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. PMID: 27747085 Ref: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. PMID: 27756406 Ref: Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. PMID: 27764839 Ref: Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. PMID: 27863474 Ref: A case report of successful diagnosis of a pulmonary nodule by a survey of oncogenic mutations; primary lung carcinoma or pulmonary metastasis? PMID: 27865146 Ref: Frequency of K-RAS and N-RAS Gene Mutations in Colorectal Cancers in Southeastern Iran PMID: 27880995 Ref: High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. PMID: 27916952 Ref: Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. PMID: 27999270 Ref: Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. PMID: 28007036 Ref: Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. PMID: 28078112 Ref: Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. PMID: 28082821 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 Ref: Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. PMID: 28356789 Ref: Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. PMID: 28848656 |
Ref: NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma. PMID: 26862952 Ref: Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. PMID: 27384156 Ref: Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. PMID: 27578453 Ref: Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates. PMID: 27609830 Ref: BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. PMID: 27815357 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. PMID: 28011498 Ref: Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. PMID: 28025078 Ref: Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. PMID: 28031175 Ref: Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. PMID: 28040715 Ref: Translating genomic profiling to gastrointestinal cancer treatment. PMID: 28067073 Ref: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. PMID: 28068936 Ref: KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. PMID: 28074351 Ref: Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. PMID: 28091917 Ref: [Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system]. PMID: 28105615 Ref: EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. PMID: 28147317 Ref: QMC-PCRx: a novel method for rapid mutation detection. PMID: 28153952 Ref: Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. PMID: 28170370 Ref: Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. PMID: 28179590 Ref: KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. PMID: 28188750 Ref: Molecular Testing for Gastrointestinal Cancer. PMID: 28219002 Ref: Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. PMID: 28222664 Ref: Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. PMID: 28243320 Ref: Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PMID: 28267766 Ref: Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. PMID: 28275037 Ref: Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC. PMID: 28292978 Ref: Intratumorous heterogeneity for RAS mutations in a treatment-naive colorectal tumour. PMID: 28314739 Ref: Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers. PMID: 28345467 Ref: SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma. PMID: 28353383 Ref: DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. PMID: 28378457 Ref: The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients. PMID: 28416767 Ref: NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer. PMID: 28433252 Ref: Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. PMID: 28446505 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. PMID: 28451421 Ref: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. PMID: 28507204 Ref: Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. PMID: 28513830 Ref: EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. PMID: 28560458 Ref: Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. PMID: 28618197 Ref: Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. PMID: 28618430 Ref: RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). PMID: 28653203 Ref: Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? PMID: 28665451 Ref: Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. PMID: 28671043 Ref: Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. PMID: 28678173 Ref: Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. PMID: 28685087 Ref: Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. PMID: 28859058 Ref: Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. PMID: 28942013 Ref: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29024937 Ref: Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. PMID: 29029407 Ref: Colorectal carcinoma with osseous metaplasia. PMID: 29029440 Ref: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. PMID: 29037218 Ref: Derivation and basic characterization of colorectal carcinoma primary cell lines. PMID: 29042709 Ref: Establishing a colorectal cancer liver metastasis patient-derived tumor xenograft model for the evaluation of personalized chemotherapy. PMID: 29094026 Ref: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. PMID: 29169325 Ref: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. PMID: 29183279 Ref: Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects. PMID: 29192596 Ref: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. PMID: 29212173 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 |
Ref: The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. PMID: 27258560 Ref: Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort. PMID: 28044264 Ref: Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. PMID: 28262927 Ref: Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. PMID: 28899979 Ref: RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. PMID: 28950295 Ref: Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity. PMID: 29027537 Ref: FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. PMID: 29046927 Ref: Association between clinicopathological characteristics and RAS mutation in colorectal cancer. PMID: 29052598 Ref: Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. PMID: 29128266 Ref: RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. PMID: 29196555 Ref: Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression. PMID: 29222172 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. PMID: 29327707 Ref: RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. PMID: 29333594 Ref: Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? PMID: 29335867 Ref: Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. PMID: 29380640 Ref: KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. PMID: 29409955 Ref: Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? PMID: 29414818 Ref: Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China. PMID: 29423347 Ref: Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. PMID: 29431699 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: Systemic Therapy for Colon Cancer. PMID: 29496087 Ref: Clinical Trials and Progress in Metastatic Colon Cancer. PMID: 29496094 Ref: Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). PMID: 29523646 Ref: Phosphorylation of p70 Ribosomal Protein S6 Kinase beta-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. PMID: 29526493 Ref: Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation. PMID: 29549923 Ref: FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. PMID: 29587749 Ref: Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. PMID: 29596542 Ref: [Prediction of EGFR blockade responses in metastatic colorectal carcinoma]. PMID: 29631407 Ref: Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. PMID: 29643917 Ref: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. PMID: 29666387 Ref: Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. PMID: 29682243 Ref: Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. PMID: 29705968 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. PMID: 29725370 Ref: Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. PMID: 29731264 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: Novel insights into transcriptional dysregulation in colorectal cancer. PMID: 29788743 Ref: Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care. PMID: 29790787 Ref: Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. PMID: 29802524 Ref: Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. PMID: 29844874 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. PMID: 29855806 Ref: Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. PMID: 29873882 Ref: Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. PMID: 29908105 Ref: Colorectal cancer genomics and designing rational trials. PMID: 29911107 Ref: Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. PMID: 29921458 Ref: Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. PMID: 29945573 Ref: Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. PMID: 29959022 Ref: Differences in gene mutations according to gender among patients with colorectal cancer. PMID: 29976257 Ref: Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. PMID: 29985199 Ref: A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer. PMID: 30026326 Ref: Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. PMID: 30029640 Ref: Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. PMID: 30036146 Ref: RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. PMID: 30037330 Ref: Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. PMID: 30042065 Ref: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. PMID: 30085422 Ref: Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates. PMID: 30130797 Ref: Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). PMID: 30150883 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. PMID: 30202242 Ref: Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. PMID: 30205948 Ref: Liquid Biopsy to Identify Actionable Genomic Alterations. PMID: 30231331 Ref: Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. PMID: 30231342 Ref: Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. PMID: 30252132 Ref: [Colorectal cancer susceptibility genetic variants in tumor free and colorectal carcinoma bearing Hungarian population. Individual predisposition to cancer]. PMID: 30277414 Ref: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. PMID: 30339194 Ref: Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. PMID: 30344942 |